Bottom line
Is AHSCX a good fund? The bottom line
AHSCX is a share class of Alger Health Sciences Fund, a managed health care sector mutual fund from Alger.
Its expense ratio is 1.96% — about $196 a year on every $10,000 invested, more expensive than 93% of health care sector funds we track.
It returned +8.2% over one year, −2.7% a year over five years, +6.7% a year over ten (as of Dec 31, 2025, per its prospectus).
With $75.4 million in net assets and 55 holdings, its largest position is Dreyfus Treasury Obligations Cash Management (6.5%) and the top 10 make up 42.3% of the portfolio.
What stands out
- No front-end sales load
What to watch
- Expensive for its category (1.96%)
- 5-year return in the bottom quarter of its category
- 12b-1 marketing fee of 1% a year
- High turnover (289% a year) can mean more taxable distributions
Updated Nov 19, 2026
What AHSCX invests in
Alger Health Sciences Fund seeks long-term capital appreciation.
The Manager believes companies undergoing Positive Dynamic Change offer the best opportunities. Positive Dynamic Change refers to companies realizing High Unit Volume Growth or companies undergoing Positive Lifecycle Change. High Unit Volume Growth companies are traditional growth companies experiencing, for example, rapidly growing demand or market dominance. Positive Lifecycle Change companies are, for example, companies benefitting from new regulations, a new product innovation or new management. Under normal circumstances, the Fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies of any market capitalization that are engaged in the health sciences sector. Equity securities include common or preferred stocks that are listed on U.S. or foreign exchanges. A company will be considered to be engaged in the health…
From the fund's prospectus (filed Mar 5, 2026).
AHSCX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| AHSCX | +8.2% | −2.7% | +6.7% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What AHSCX costs
On a $10,000 investment, AHSCX's 1.96% expense ratio costs about $196 a year. The prospectus estimates $2,285 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
AHSCX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Dreyfus Treasury Obligations Cash Management | 6.51% |
| 2 | Impulse Dynamics Ireland | 4.27% |
| 3 | Merck & Company Inc MRK | 4.18% |
| 4 | Welltower Inc WELL | 4.12% |
| 5 | Johnson & Johnson JNJ | 4.06% |
| 6 | Thermo Fisher Scientific Inc TMO | 4.00% |
| 7 | Bruker Corp BRKR | 3.98% |
| 8 | Illumina Inc ILMN | 3.95% |
| 9 | Cvs Health Corp CVS | 3.67% |
| 10 | Unitedhealth Group Inc UNH | 3.61% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 42.3% of the fund. See all top 25 holdings and asset mix →